CLAIMS

1. A stable pharmaceutical composition comprising an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant,
wherein the following (1) and/or (2) is contained as the anti-human TSLP receptor antibody:
(1) an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence of SEQ ID NO: 3, and
(2) an anti-human TSLP receptor antibody consisting of amino acid sequences of an antibody generated by a post-translational modification of the anti-human TSLP receptor antibody of (1),
wherein the pharmaceutically acceptable buffer is one or two selected from the group consisting of phosphoric acid and citric acid, and
wherein the pharmaceutical composition does not comprise glutamic acid and sucrose.

2. The pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable buffer is phosphoric acid.

3. The pharmaceutical composition according to claim 1 or 2, wherein the concentration of the pharmaceutically acceptable buffer is 5 to 100 mmol/L.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the pharmaceutical composition is a liquid preparation, or a lyophilized preparation or a spray-dried preparation.

5. The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is a liquid preparation.

6. The pharmaceutical composition according to claim 4, wherein when the pharmaceutical composition is a liquid preparation, a pH of the liquid preparation is 5 to 6, or when the pharmaceutical composition is a lyophilized preparation or a spray-dried preparation, a pH of a solution after reconstituting the preparation in water is 5 to 6.

7. The pharmaceutical composition according to claim 6, wherein the pharmaceutical composition is a liquid preparation, and the pH of the liquid preparation is 5 to 6.

8. The pharmaceutical composition according to any one of claims 1 to 7, wherein the concentration of the arginine or a pharmaceutically acceptable salt thereof is 700 mmol/L or less.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the surfactant is one, or two or more selected from the group consisting of polysorbates and poloxamer 188.

10. The pharmaceutical composition according to any one of claims 1 to 9, wherein the surfactant is polysorbate 80.

11. The pharmaceutical composition according to any one of claims 1 to 10, wherein a content of the surfactant is 0.001 to 1% (w/v).

12. The pharmaceutical composition according to any one of claims 1 to 11, wherein the content of the surfactant is 0.01 to 0.2% (w/v).

13. The pharmaceutical composition according to any one of claims 4 to 12, wherein when the pharmaceutical composition is a liquid preparation, a content of the anti-human TSLP receptor antibody is 0.007 to 2 mmol/L, or when the pharmaceutical composition is a lyophilized preparation or a spray-dried preparation, a content of a solution after

reconstituting the preparation in water is 0.007 to 2 mmol/L.

14. The pharmaceutical composition according to any one of claims 1 to 13, when the pharmaceutical composition is stored, each content of a degradant and a multimer is 10% or less, or a content of a chemically modified substance is 50% or less.

15. The pharmaceutical composition according to claim 1, comprising an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence of SEQ ID NO: 3.

16. The pharmaceutical composition according to claim 1, comprising an anti-human TSLP receptor antibody consisting of amino acid sequences of an antibody generated by a post-translational modification of an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence of SEQ ID NO: 3.

17. The pharmaceutical composition according to claim 1, comprising an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence of amino acids 1-447 of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence of SEQ ID NO: 3.

18. The pharmaceutical composition according to claim 1, comprising an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence of SEQ ID NO: 3, and an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence of amino acids 1-447 of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence of SEQ ID NO: 3.